Hederagenin

ArtNr	HY-N0256-25mg
Hersteller	MedChem Express
CAS-Nr.	465-99-6
Menge	25 mg
Quantity options	10 mM/1 mL 10 mg 25 mg 50 mg 5 mg
Kategorie	Metabolism Diabetes Glucose Homeostasis Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	99.95
Citations	[1]Su-Hong Lu et al. Experimental Study of Antiatherosclerosis Effects with Hederagenin in Rats. Evid Based Complement Alternat Med, 2015, Oct 19\|[2]Diego Rodríguez-Hernández et al. Hederagenin as a triterpene template for the development of new antitumor compounds. Eur J Med Chem, 2015 Nov 13, 105:57-62\|[3]Chul Won Lee et al. Hederagenin, a major component of Clematis mandshurica Ruprecht root, attenuates inflammatory responses in RAW 264.7 cells and in mice. Int Immunopharmacol, 2015 Dec, 29(2):528-37.\|[4]Liu BX, et al. Hederagenin from the leaves of ivy (Hedera helix L.) induces apoptosis in human LoVo colon cells through the mitochondrial pathway. BMC Complement Altern Med. 2014 Oct 24;14:412.\|[5]Kim GJ, et al. Hederagenin Supplementation Alleviates the Pro-Inflammatory and Apoptotic Response to Alcohol in Rats. Nutrients. 2017 Jan 6;9(1):41.\|[6]Wang K, et al. Hederagenin potentiated cisplatin- and paclitaxel-mediated cytotoxicity by impairing autophagy in lung cancer cells. Cell Death Dis. 2020 Aug 13;11(8):611.
Smiles	CC1(C)CC[C@@](CC[C@]2(C)C3=CC[C@@]4([H])[C@@]2(C)CC[C@]5([H])[C@]4(C)CC[C@H](O)[C@]5(CO)C)(C(O)=O)[C@@]3([H])C1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Natural Products
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	COX; NF-κB
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	472.70
Product Description	Hederagenin is a triterpenoid saponin with orally active and antitumor activity. Hederagenin can inhibit the expression of iNOS, COX-2, and NF-κB in cells induced by LPS stimulation. Hederagenin also increases ROS production in cancer cells, disrupts mitochondrial membrane potential, and induces apoptosis. Hederagenin also sensitizes cancer cells to Cisplatin (HY-17394) and Paclitaxel (HY-B0015), enhancing induced apoptosis. Hederagenin also has preventive potential against alcoholic liver injury[1][2][3][4][5][6].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 50 mg/mL (ultrasonic)
Manufacturer - Pathway	Immunology/Inflammation; NF-κB
Clinical information	No Development Reported

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-N0256-25mg-safety-datasheet.pdf